natgillin/translations-raw huggingface dataset:
Vial: 3 ml vial, colourless glass type 1 Closure: lyophilisate stopper, rubber (latex free) Seal: aluminium seal with flip-off cap
Viala: 3 ml viala, brezbarvno steklo tipa 1 Zamašek: zamašek iz gume (brez lateksa)
Vial: Suspension doses (1 ml)
viala: suspenzija odmerka (1 ml)
vials
EU/1/4/301/004
vials
viali
Vials (1 dose lyophilisate)
Viala (1 odmerek liofilizata)
Vials (10, 20 or 50 ml)
Viale (10, 20 ali 50 ml viale iz PET)
Vials (100, 200, 250 or 500 ml PET vials)
Viale (100, 200, 250 ali 500 ml viale iz PET)
vials (multipack) 1 bottle
1 steklenica
Vials (only Humalog Mix50)
Viale (samo Humalog Mix50)
Vials (type I glass)
Viale (steklo tipa I)
vials + 2 vials
2 vial + 2 vial
vials and solvent required for preparation of one dose*
viale in vehikel, potrebni za pripravo enega odmerka
Vials besides Humalog Mix50
Viale poleg Humalog Mix50
Vials contain 10 ml, 50 ml or 100 ml.
Viale vsebujejo 10 ml, 50 ml ali 100 ml zdravila
Vials contain 500 mg as a 10 mg/mL solution of olaratumab.
Viale vsebujejo 500 mg olaratumaba v obliki 10 mg/ml raztopine.
Vials contain 500 mg as a 10 mg/mL solution of olaratumab; calculate the dose and volume of olaratumab needed to prepare the infusion solution.
Viale vsebujejo 500 mg olaratumaba v obliki 10 mg/ml raztopine; izračunajte odmerek in prostornino olaratumaba, ki sta potrebna za pripravo raztopine za infundiranje.
Vials containing Humalog Mix25 should be rotated in the palms of the hands before use to resuspend insulin until it appears uniformly cloudy or milky.
Viale, ki vsebujejo zdravilo Humalog Mix25, je treba pred uporabo vrteti med dlanmi rok, da ponovno suspendirate insulin, dokler ni enakomerno motnega ali mlečnega videza.
Vials containing Humalog Mix25 should be rotated in the palms of the hands before use to resuspend the insulin until it appears uniformly cloudy or milky.
Viale, ki vsebujejo zdravilo Humalog Mix25 je treba pred uporabo vrteti med dlanmi rok, da ponovno suspendirate insulin, dokler ni enakomerno motnega ali mlečnega videza.
Vials containing Humalog Mix50 should be rotated in the palms of the hands before use to resuspend insulin until it appears uniformly cloudy or milky.
Viale, ki vsebujejo zdravilo Humalog Mix50, je treba pred uporabo vrteti med dlanmi rok, da ponovno suspendirate insulin, dokler ni enakomerno motnega ali mlečnega videza.
Vials containing Humalog Mix50 should be rotated in the palms of the hands before use to resuspend the insulin until it appears uniformly cloudy or milky.
Viale, ki vsebujejo zdravilo Humalog Mix50, je treba pred uporabo vrteti med dlanmi rok, da ponovno suspendirate insulin, dokler ni enakomerno motnega ali mlečnega videza.
Vials for the powder: 10 doses, 50 doses, 100 doses
Viala za prašek: 10 odmerkov, 50 odmerkov, 100 odmerkov
Vials in use should be stored below 30C.
Viale, ki jih uporabljate, shranjujte pri temperaturi do 30 C.
VIALS OF 10 AND 20 ML
VIALE Z 10 IN 20 ML
Vials of 10 mL are available as a pack of 2 vials.
10-ml viale so na voljo v pakiranju po 2.
Vials of 100, 200 and 500 ml
Viale po 100, 200 in 500 ml
Vials of 20 and 50 ml
Viale po 20 in 50 ml
vials of powder.
viali s praškom
Vials of suspension
Viale s suspenzijo
Vials should be allowed to warm to room temperature (18°C -22°C) for a minimum of 30 minutes and be gently inverted to resuspend the particles immediately prior to withdrawal from the vial.
Viale pustite najmanj 30 minut, da se ogrejejo na sobno temperaturo (18°C – 22 °C), nato jih nežno obrnite, da ponovno suspendirate delce, preden zdravilo vzamete iz viale.
Vials should be thawed and stored in the original carton until administration in order to protect from light.
Viale je treba odtajati in do uporabe shranjevati v originalni škatli za zagotovitev zaščite pred svetlobo.
Vials should not be shaken.
Ne pretresajte jih.
vials vials
viale vial
vials with chlorobutyl stopper and aluminium seal
tipa I s klorobutilnim zamaškom in aluminijasto kapico
vials with powder and 14 pre-filled syringes with 1.2 ml solvent.
vial s praškom in 14 napolnjenih injekcijskih brizg z 1,2 ml vehikla.
Vials years.
Viale leta
Vials {100, 200 and 500 ml}
Viale (100, 200 in500 ml}
Vials {20 and 50 ml}
Viale (20 in 50 ml
Vials: 3 years Diluted solution:
Viale: 3 leta Razredčena raztopina:
VIBATIV 250 mg powder for concentrate for solution for infusion EU/1/11/705/001
VIBATIV 250 mg prašek za koncentrat za raztopino za infundiranje
VIBATIV 250 mg powder for concentrate for solution for infusion telavancin
VIBATIV 250 mg prašek za koncentrat za raztopino za infundiranje telavancin
VIBATIV 250 mg powder for concentrate for solution for infusion VIBATIV 750 mg powder for concentrate for solution for infusion telavancin
VIBATIV 250 mg prašek za koncentrat za raztopino za infundiranje VIBATIV 750 mg prašek za koncentrat za raztopino za infundiranje telavancin
VIBATIV 750 mg powder for concentrate for solution for infusion EU/1/11/705/002
VIBATIV 750 mg prašek za koncentrat za raztopino za infundiranje
VIBATIV 750 mg powder for concentrate for solution for infusion telavancin
VIBATIV 750 mg prašek za koncentrat za raztopino za infundiranje telavancin
VIBATIV is indicated for the treatment of adults with nosocomial pneumonia (NP) including ventilator associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus (MRSA).
Zdravilo VIBATIV je indicirano za zdravljenje odraslih oseb z bolnišnično pljučnico, vključno z ventilatorsko pljučnico, za katero je znano oz. za katero se sumi, da jo je povzročil na meticilin odporen sev Staphylococcus aureus (MRSA).
Vibativ is used only when the infection is known or believed to be caused by bacteria called ‘methicillin-resistant Staphylococcus aureus’ (MRSA) and when other treatments (such as other antibiotics) are not suitable.
Zdravilo Vibativ se uporablja samo v primerih, ko je znano ali se sumi, da je okužbo povzročila „na meticilin odporna bakterija Staphylococcus aureus“(MRSA) in kadar zdravljenje z drugimi zdravili (na primer drugimi antibiotiki) ni primerno.
VIBATIV may cause the following side effects:
Zdravilo VIBATIV lahko povzroči naslednje neželene učinke:
Vibativ should be provided to CHMP no later than 31 December 2017.
predloženi CHMP najpozneje 31. decembra 2017.
Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 31.25x109 bacteria* Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 31.25x109 bacteria* Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 31.25x109 bacteria* Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 31.25x109 bacteria*
Vibrio cholerae O1 Inaba, klasični biotip (inaktiviran s toploto) 31,25 x 109 bakterij* Vibrio cholerae O1 Inaba, biotip El Tor (inaktiviran s formalinom) 31,25 x 109 bakterij* Vibrio cholerae O1 Ogawa, klasični biotip (inaktiviran s toploto) 31,25 x 109 bakterij
Victoria 3047 AUSTRALIA
Victoria 3047 AVSTRALIJA
Victoza 6 mg/ml solution for injection in pre­filled pen
Victoza 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Victoza 6 mg/ml solution for injection in pre­filled pen
Victoza 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku liraglutid
Victoza 6 mg/ml solution for injection in pre­filled pen Liraglutide
Victoza 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku liraglutid
Victoza can be added to existing metformin or to a combination of metformin and thiazolidinedione therapy.
Zdravilo Victoza se lahko uporablja kot dodatek pri zdravljenju z metforminom ali pri kombinaciji metformina in tiazolidindiona.
Victoza can be added to existing sulfonylurea or to a combination of metformin and sulfonylurea therapy or a basal insulin.
Zdravilo Victoza se lahko uporablja kot dodatek pri zdravljenju s sulfonilsečnino, kombinacijo metformina in sulfonilsečnine ali z bazalnim insulinom.
Victoza can be administered with needles up to a length of 8 mm and as thin as 32G. The pen is designed to be used with NovoFine or NovoTwist disposable needles.
Zdravilo Victoza je mogoče injicirati z iglo dolžine do 8 mm in ne tanjšimi kot 32G. Injekcijski peresnik je namenjen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo.
Victoza can currently not be recommended for use in patients with severe renal impairment including patients with end­stage renal disease (see section 5.2).
Zdravila Victoza trenutno ni mogoče priporočiti za zdravljenje bolnikov s hudo okvaro ledvic, vključno z bolniki s končno odpovedjo ledvic (glejte poglavje 5.2).
Victoza has no or negligible influence on the ability to drive and use machines.
Zdravilo Victoza nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Victoza is a solution for injection that contains the active substance liraglutide.
Zdravilo Victoza je raztopina za injiciranje, ki vsebuje zdravilno učinkovino liraglutid.
Victoza is given by the patient once a day by injection under the skin in the abdomen, thigh or upper arm.
Zdravilo Victoza si bolnik injicira v podkožje enkrat na dan v trebuh, stegno ali nadlaket.
Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control as:
Zdravilo Victoza je namenjeno zdravljenju odraslih s sladkorno boleznijo tipa 2 za uravnavanje glikemije kot:
Victoza is not recommended in children and adolescents under 18 years as the safety and efficacy in this age group have not yet been established.
Uporaba zdravila Victoza pri otrocih in mladostnikih, mlajših od 18 let ni priporočljiva, saj varnost in učinkovitost zdravila v tej starostni skupini še nista bili dokazani.
Victoza is supplied as a clear, colourless or almost colourless, solution for injection in a pre­filled pen.
Zdravilo Victoza je na voljo kot bistra, brezbarvna ali skoraj brezbarvna raztopina za injiciranje v napolnjenem injekcijskem peresniku.
Victoza is used in adults who have type 2 diabetes to control their blood glucose (sugar) level.
Zdravilo Victoza se uporablja za zdravljenje odraslih s sladkorno boleznijo tipa 2 za uravnavanje ravni glukoze (sladkorja) v krvi.
Victoza is used on its own if your blood sugar is not properly controlled by diet and exercise alone, and you cannot use metformin (another diabetes medicine).
Zdravilo Victoza se uporablja sámo, če krvni sladkor z dieto in s telesno vadbo ni zadostno urejen, metformina (drugega zdravila za zdravljenje sladkorne bolezni) pa ne morete uporabljati.
Victoza is used with other medicines for diabetes when they are not enough to control your blood sugar levels.
Zdravilo Victoza se uporablja skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (če ta
Victoza should not be used if it does not appear clear and colourless or almost colourless.
Zdravila Victoza ne smete uporabiti, če raztopina ni bistra in brezbarvna ali skoraj brezbarvna.
Victrelis 800 mg single dose)
+ zdravilo Victrelis 800 mg enkratni
Victrelis 800 mg single dose)
odmerek + zdravilo Victrelis 800 mg
Victrelis 800 mg three times daily
+ zdravilo Victrelis 800 mg trikrat na dan večkratni odmerek
Victrelis 800 mg three times daily
odmerek + zdravilo Victrelis 800 mg
Victrelis 800 mg three times daily)
Maravirok* (maravirok 150 mg dvakrat na dan + zdravilo Victrelis 800 mg trikrat na dan)
Victrelis 800 mg three times daily)
odmerek + zdravilo Victrelis 800 mg
Victrelis 800 mg three times daily)
trikrat na dan)
Victrelis 800 mg three times daily)
zdravilo Victrelis 800 mg trikrat na
Victrelis 800 mg three times daily)
zdravilo Victrelis 800 mg trikrat na dan)
Victrelis and should be
podlagi natančnega nadzora
Victrelis contains the active ingredient boceprevir which helps to fight against hepatitis C infection by stopping the virus multiplying.
Zdravilo Victrelis vsebuje zdravilno učinkovino boceprevir, ki pomaga zdraviti okužbo s hepatitisom C tako, da ustavi razmnoževanje virusa.
Victrelis does not affect your ability to drive or use tools or machines.
Zdravilo Victrelis ne vpliva na sposobnost vožnje in upravljanja s stroji.
Victrelis does not inhibit or induce the other enzymes of the CYP450.
Zdravilo Victrelis ne zavira in ne inducira drugih encimov CYP450.
Victrelis has not been
zdravilom Victrelis niso
Victrelis in combination with peginterferon alfa and ribavirin is not recommended in patients who have platelet count < 100,000/mm3 and/or serum albumin < 35 g/L and/or signs of coagulapathy (International Normalized Ratio (INR) > 1.7) at baseline.
Uporaba zdravila Victrelis v kombinaciji s peginterferonom alfa in ribavirinom ni priporočljiva pri bolnikih, ki imajo v izhodišču število trombocitov < 100.000/mm3 in/ali serumski albumin < 35 g/l in/ali znake koagulopatije (internacionalno normalizirano razmerje (INR) > 1,7).
Victrelis in combination with ribavirin and peginterferon alfa is contraindicated in women who are pregnant (see section 4.3).
Zdravilo Victrelis v kombinaciji z ribavirinom in peginterferonom alfa je kontraindicirano pri nosečnicah (glejte poglavje 4.3).
Victrelis inhibits the direct replication of the virus and contributes in this way to lowering the amount of hepatitis C virus in your body.
Zdravilo Victrelis zavira neposredno razmnoževanje virusa in na tak način pomaga zmanjšati količino virusa hepatitis C v vašem telesu.
Victrelis is always taken in combination with peginterferon alfa and ribavirin.
Zdravilo Victrelis se vedno jemlje v kombinaciji s peginterferonom alfa in ribavirinom.
Victrelis is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy (see sections 4.4 and 5.1).
Zdravilo Victrelis je indicirano za zdravljenje kronične okužbe s hepatitisom C genotipa 1 v kombinaciji s peginterferonom alfa in ribavirinom pri odraslih bolnikih s kompenzirano jetrno boleznijo, ki še niso bili zdravljeni ali pri njih predhodno zdravljenje ni bilo uspešno (glejte poglavji 4.4 in 5.1).
Victrelis is to be taken orally with food (a meal or light snack).
Zdravilo Victrelis se jemlje peroralno s hrano (obrok ali lahek prigrizek).
Victrelis is used to treat adults with chronic (long-term) hepatitis C genotype 1 (a disease of the liver due to infection with the hepatitis C virus) in combination with two other medicines, peginterferon alfa and ribavirin.
Zdravilo Victrelis se uporablja za zdravljenje odraslih s kroničnim (dolgotrajnim) hepatitisom C genotipa 1 (boleznijo jeter zaradi okužbe z virusom hepatitisa C) v kombinaciji z dvema drugima zdraviloma, peginterferonom alfa in ribavirinom.
Victrelis may be used in adults who are previously untreated for HCV infection or who have previously used medicines called ‘interferons’ and ‘pegylated interferons’.
Zdravilo Victrelis se lahko uporablja pri odraslih, ki zaradi okužbe s HCV še niso bili zdravljeni, in pri odraslih, ki so prej že prejemali zdravila, imenovana "interferoni" in "pegilirani interferoni".
Victrelis must not be administered in the absence of peginterferon alfa and ribavirin.
Zdravila Victrelis se ne sme uporabiti brez peginterferona alfa in ribavirina.
Victrelis must not be used by itself.
Zdravila Victrelis se ne sme uporabljati samega.
Victrelis or rilpivirine is
zdravila Victrelis ali
Victrelis should be
Victrelis, je treba ustrezno
Victrelis with an oral
očasna uporaba zdravila
Vidaza 25 mg/mL powder for suspension for injection
Vidaza 25 mg/ml prašek za suspenzijo za injiciranje
Vidaza contains the active substance ‘azacitidine’.
Zdravilo Vidaza vsebuje zdravilno učinkovino 'azacitidin'.
Vidaza is a white powder for suspension for injection and is supplied in a glass vial containing 100 mg of azacitidine.
Zdravilo Vidaza je bel prašek za suspenzijo za injiciranje, ki je na voljo v stekleni viali, ki vsebuje 100 mg azacitidina.
Vidaza is an anti-cancer agent which belongs to a group of medicines called ‘anti-metabolites’.
Zdravilo Vidaza je sredstvo proti raku, ki pripada skupini zdravil, ki se imenujejo 'antimetaboliti'.
Vidaza is given every day for one week, followed by a rest period of 3 weeks.
Zdravilo Vidaza boste en teden prejemali vsak dan, nato sledi tritedensko obdobje mirovanja.
Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
Zdravilo Vidaza je indicirano za zdravljenje odraslih bolnikov, ki niso primerni za presaditev krvotvornih matičnih celic (PKMC) s/z: mielodisplastičnimi sindromi (MDS) z vmesno stopnjo 2 in visoko stopnjo tveganja po Mednarodnem prognostičnem sistemu ocenjevanja (IPSS - International Prognostic Scoring System), kronično mielomonocitno levkemijo (KMMoL) z 10-29 % blastnih celic kostnega mozga brez mieloproliferativne bolezni, akutno mieloično levkemijo (AML) z 20-30 % blastnih celic in displazijo več celičnih linij po razvrstitvi Svetovne zdravstvene organizacije (SZO),
Vidaza is not recommended for use in children and adolescents below the age of 18.
Uporaba zdravila Vidaza ni priporočljiva pri otrocih in mladostnikih, mlajših od 18 let.
Vidaza is used for the treatment of adults with the following diseases, if they cannot have haematopoietic stem cell transplantation (when the patient receives stem cells to restore the bone marrow’s ability to produce healthy blood cells): myelodysplastic syndromes, a group of conditions where too few blood cells are produced by the bone marrow.
Zdravilo Vidaza se uporablja za zdravljenje odraslih z naslednjimi boleznimi, če jim ni mogoče presaditi hematopoetskih (krvotvornih) matičnih celic (pri čemer bolnik prejme matične celice, ki pomagajo obnoviti sposobnost kostnega mozga, da proizvaja zdrave krvne celice): z mielodisplastičnimi sindromi, tj. skupino obolenj, pri katerih kostni mozeg ne ustvarja dovolj velikega števila krvnih celic.
Vidaza is used in adults who are not able to have a stem cell transplantation to treat: higher-risk myelodysplastic syndromes (MDS). chronic myelomonocytic leukaemia (CMML). acute myeloid leukaemia (AML).
Zdravilo Vidaza se uporablja pri odraslih bolnikih, pri katerih ni možna presaditev matičnih celic, za zdravljenje: mielodisplastičnih sindromov (MDS) z večjim tveganjem; kronične mielomonocitne levkemije (KMMoL); akutne mieloične levkemije (AML).
Vidaza is used in patients with an intermediate to high risk of progressing to AML or death; chronic myelomonocytic leukaemia (CMML, a cancer affecting white blood cells called monocytes).
Zdravilo Vidaza se uporablja pri bolnikih s srednjo in visoko stopnjo tveganja za napredovanje bolezni do akutne mieloične levkemije ali smrti; s kronično mielomonocitno levkemijo (KMML, rakom, ki prizadene bele krvničke, imenovane monociti).
Vidaza plus BSC (n=241) was compared to CCR.
Razmerje ogroženosti za učinek zdravljenja je bilo 0,85 (95 % IZ= 0,69; 1,03).
Vidaza treatment was associated with a median time to death or transformation to AML of
Zdravilo Vidaza skupaj z BSC (n=241) so primerjali s CCR.
Viekirax
itrakonazolom,
Viekirax
odmerek pravastatina
Viekirax
Viekirax z
Viekirax
Viekirax z dasabuvirje
Viekirax +
UČINEK
Viekirax 12.5 mg / 75 mg / 50 mg film-coated tablets ombitasvir / paritaprevir / ritonavir
Viekirax 12,5 mg/75 mg/50 mg filmsko obložene tablete ombitasvir/paritaprevir/ritonavir
Viekirax 12.5 mg / 75 mg / 50 mg tablets ombitasvir / paritaprevir / ritonavir
Viekirax 12,5 mg/75 mg/50 mg filmsko obložene tablete ombitasvir/paritaprevir/ritonavir
Viekirax 12.5 mg/75 mg/50 mg film-coated tablets ombitasvir/paritaprevir/ritonavir
Viekirax 12,5 mg/75 mg/50 mg filmsko obložene tablete ombitasvir/paritaprevir/ritonavir
Viekirax and dasabuvir (12 weeks)
Viekirax in dasabuvir (12 tednov)
Viekirax and dasabuvir 12 weeks
Viekirax in dasabuvir 12 tednov
Viekirax and dasabuvir for 12 weeks
Viekirax in dasabuvir 12 tednov
Viekirax and dasabuvir in combination with ribavirin is recommended for 24 weeks in liver transplant recipients with genotype 1 HCV infection.
Zdravilo Viekirax in dasabuvir sta skupaj z ribavirinom pri prejemnikih presajenih jeter, okuženih s HCV genotipa 1, priporočljiva 24 tednov.
Viekirax and dasabuvir with RBV
Viekirax in dasabuvir z RBV
Viekirax and dasabuvir with RBV for 12 weeks
Viekirax in dasabuvir z RBV 12 tednov
Viekirax can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C.
Izdaja zdravila Viekirax je le na recept, zdravljenje pa mora uvesti in spremljati zdravnik, ki ima izkušnje z zdravljenjem bolnikov s kroničnim hepatitisom C.
Viekirax has been shown to be effective against genotypes 1a and 1b and genotype 4.
Zdravilo Viekirax se je izkazalo za učinkovito proti genotipoma 1a in 1b ter genotipu 4.
Viekirax has not been studied in HCV-infected patients on dialysis.
Zdravilo Viekirax ni raziskano pri bolnikih, ki so okuženi s HCV in se zdravijo z dializo.
Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of liver caused by the hepatitis C virus.
Zdravilo Viekirax je protivirusno zdravilo, ki se uporablja v kombinaciji z drugimi zdravili za zdravljene odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. nalezljivo boleznijo jeter, ki jo povzroča virus hepatitisa C.
Viekirax is contraindicated in patients with severe hepatic impairment (Child-Pugh C) (see sections 4.2, 4.3, 4.8 and 5.2).
Zdravilo Viekirax je kontraindicirano pri bolnikih s hudo okvaro jeter (Child-Pugh C) (glejte poglavja 4.2, 4.8 in 5.2.).
Viekirax is not recommended in patients with moderate hepatic impairment (Child-Pugh B) (see sections
Uporaba zdravila Viekirax pri bolnikih z zmerno okvaro jeter (Child-Pugh B) se ne priporoča (glejte poglavji 4.4 in
Viekirax must not be used in patients with severe liver impairment and in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives.
Zdravilo Viekirax se ne sme predpisovati bolnikom s hudo okvaro jeter in ženskam, ki jemljejo etinilestradiol, tj. vrsto estrogena, ki je v hormonskih kontracepcijskih sredstvih.
Viekirax ombitasvir / paritaprevir / ritonavir
Viekirax ombitasvir, paritaprevir in ritonavir.
Viekirax should not be used during pregnancy or in women of childbearing potential not using effective contraception.
Zdravilo Viekirax se ne sme uporabljati med nosečnostjo ali pri ženskah v rodni dobi brez učinkovite kontracepcije.
Viekirax tablets are pink, oblong film-coated tablets of dimmensions 18.8 mm x 10.0 mm, marked with ‘AV1’.
Tablete zdravila Viekirax so rožnate, podolgovate, filmsko obložene tablete velikosti 18,8 mm x 10,0 mm, z oznako "AV1".
Viekirax tablets are usually taken with other anti-viral medicines such as “dasabuvir” and “ribavirin”.
Tablete zdravila Viekirax se običajno jemljejo z drugimi protivirusnimi zdravili, kot sta “dasabuvir” in “ribavirin”.
Viekirax with or without
očasno daje s
Viekirax with or without
Viekirax z
Viekirax with or without
zdravilom Viekirax z
Viekirax with or without dasabuvir
ali brez dasabuvirja in
Viekirax with or without dasabuvir
UPORABL JENO Z
Viekirax with or without dasabuvir.
kombinacijo Viekirax z ali brez dasabuvirja.
Viekirax with or without dasabuvir.
zdravila Viekirax z dasabuvirjem ali brez
Viekirax with rilpivirine once daily should only be considered in patients without known QT- prolongation, and without other QT-prolongation co- medications.
rilpivirinom enkrat na dan pride v poštev le pri bolnikih brez znanega podaljšanja intervala QT, ki ob tem tudi ne uporabljajo kakšnih drugih zdravil, ki podaljšajo interval
Viekirax without
Viekirax brez dasabuvirja
Viekirax without dasabuvir
Odmerka zdravila Viekirax z
Viekirax without dasabuvir
Viekirax brez dasabuvirja
Viekirax without dasabuvir
Viekirax z ali brez dasabuvirja
Viekirax without dasabuvir
zdravilom Viekirax in